BioCentury
ARTICLE | Clinical News

MyoKardia's heart failure candidate shows proof of mechanism in Phase Ia

November 2, 2018 8:04 PM UTC

MyoKardia Inc. (NASDAQ:MYOK) reported data from a Phase Ia trial in healthy volunteers showing that heart failure candidate MYK-491 increased cardiac contractility by 5-20% across multiple echocardiographic parameters with minimal effect on diastolic function. The Australian trial enrolled 64 healthy volunteers to receive placebo or single ascending doses of oral MYK-491.

The company expects top-line data this quarter from the Phase Ib portion of a Phase Ib/IIa trial evaluating single ascending doses MYK-491 in patients with stable heart failure. Data are expected in late 2019 from the Phase IIa portion evaluating multiple ascending doses of MYK-491 in stable heart failure patients. MYK-491 is a small molecule allosteric modulator of cardiac myosin...

BCIQ Company Profiles

MyoKardia Inc.

Sanofi

BCIQ Target Profiles

Cardiac myosin